A filing with the state details the Columbus job cuts for a biotech cutting more than one-third of its workforce.

Companies sometimes miss the mark when it comes to telling employees they’re out of a job. From accidental goodbyes to ...

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

The FDA appears to have won its staring contest with Sarepta over shipments of Elevidys, after the company blinked and agreed ...

Sarepta Therapeutics is laying off 500 staffers, or 36% of its workforce, as part of a strategic restructuring aiming to save $400 million annually. | Sarepta Therapeutics has laid off 500 staffers, ...

Sarepta Therapeutics Inc. shares soared after the company said it was cutting more than a third of its workforce and that its ...

Sarepta Therapeutics has paused U.S. shipments of its gene therapy Elevidys after two teenagers with Duchenne muscular ...

By Bhanvi Satija (Reuters) -Shares of Sarepta Therapeutics declined 17% in early trading on Friday after another patient who had received an experimental gene therapy died, deepening investor concerns ...

Sarepta Therapeutics said on Monday it will pause all shipments of Elevidys in the United States after two teenage boys with a rare condition called Duchenne muscular dystrophy, who had received the ...

On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

Sarepta agrees to FDA's black box warning and announces major restructuring, including job cuts and cost-saving measures to ...